[
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): 2, 4, 6, 7. Well, no, we have six because both four I don't think is a person. So, I don't think those. Yeah, we're missing someone. Let me see. Pamela is here, David is here. ",
        "annotations": {
            "identify gap": "Rosa explicitly states that they are missing someone.",
            "process management": "Rosa is managing the process of accounting for team members."
        }
    },
    {
        "utterance": "Pamela Chang (Cornell): I guess we can get started with introductions. ",
        "annotations": {
            "process management": "This code applies because Pamela is managing the meeting flow by suggesting they get started with introductions."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): And if we're missing someone, that someone will, you know, come in the meantime. Is that okay? So I'll point, I'll point and tell you to talk so you don't start talking all at the same time. Dave, do you want to introduce yourself? ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by suggesting they proceed and planning to manage the discussion.",
            "encourage participation": "The speaker invites Dave to introduce himself, encouraging participation."
        }
    },
    {
        "utterance": "Dave Durgan- Baylor College of Medicine: Sure. Uh, Dave Durgan, Baylor College of Medicine. Um, I'm a cardiovascular physiologist. My lab is interested in stroke, hypertension, uh, cerebral small vessel disease. And in the last eight years or so we've become interested in how disruptions of the microbiota can uh contribute to these disease states, primarily through the uh gut inflammation access, but also um communication to brain regions that are important in cardiovascular regulation. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their own expertise as a cardiovascular physiologist and describes their lab's interests.",
            "develop idea": "The speaker elaborates on their research interests and directions, building on their stated expertise."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): That's amazing. You and I should talk later. Sound good. Okay. ",
        "annotations": {
            "Supportive response": "The utterance expresses a positive evaluation with 'That's amazing'.",
            "Encourage participation": "The speaker invites Dave for a future conversation with 'You and I should talk later'."
        }
    },
    {
        "utterance": "Dave Durgan- Baylor College of Medicine: Sound good. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or validation of Rosa's suggestion to talk later."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Um, all right, um, uh, Faranak. Faranak. I said it wrong, I'm sorry. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Faranak Fattahi, UCSF: Faranak, yes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a simple acknowledgment without adding new content or engaging in discussion."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): No, no, that was perfect. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes Faranak's input (correcting the pronunciation of her name)."
        }
    },
    {
        "utterance": "Faranak Fattahi, UCSF: My name is Faranak Fattahi. I'm from UCSF. So my lab um develops organoids models, organoid models from stem cells of the peripheral nervous system, particularly the enteric nervous system, and we're interested in figuring out how these different enteric neurons and glia within these organoids are affected in disease. So in the gut those would be motility diseases that, you know, lead to abnormalities in movement of the gut tube and the muscle tissue. We're also interested in figuring out how neurological diseases like Parkinson's and Alzheimer's and um other neurodegenerative diseases manifest in the enteric nervous system. So that's just a brief overview. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their own background and expertise related to their work at UCSF."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Thank you. That was that was great. Erin. ",
        "annotations": {
            "Supportive Response": "Rosa expresses a positive evaluation of Faranak's introduction.",
            "Process Management": "Rosa moves on to the next person in the meeting, managing the flow of introductions."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): Hi, I'm Erin Longbrake. I'm at Yale. I'm a neuroimmunologist. My research is mainly in multiple sclerosis. Um, and I'm interested in detecting the disease before it has caused damage to the nervous system. So I'm interested in the microbiome both as something that might facilitate some of the genetic environmental interactions that lead to the immune disregulation of MS. I'm also interested in in it as a biomarker of something that may be able to help us detect um when something first starts to go awry that ultimately would lead to autoimmunity. ",
        "annotations": {
            "signal expertise": "Erin explicitly states her own expertise and qualifications as a neuroimmunologist.",
            "None": "No other code directly and explicitly applies to this introductory utterance."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): That's great. Thank you, Pamela. ",
        "annotations": {
            "supportive response": "The speaker expresses a positive evaluation of a group member's contribution.",
            "acknowledge contribution": "The speaker verbally recognizes another group member's input."
        }
    },
    {
        "utterance": "Pamela Chang (Cornell): Hi, my name is Pamela Chang and um I'm an assistant professor at Cornell in Ithica. Um, my lab is interested in developing chemical tools to uh characterize or study the metabolism of the gut microbiome. And we also look at small molecule metabolites that bacteria in the gut make and how that modulates host immune responses in inflammatory diseases and also in infection. ",
        "annotations": {
            "signal expertise": "Pamela explicitly states her position as an assistant professor and describes her lab's focus areas, indicating her expertise."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): That's great. Thank you. Um, uh, Lian. Ilyan. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges a contribution with 'That's great. Thank you.'",
            "encourage participation": "The speaker encourages participation by calling on the next person ('Lian. Ilyan.').",
            "process management": "The speaker manages the meeting flow by moving to the next introduction."
        }
    },
    {
        "utterance": "Iliyan Iliev, WCM, Cornell University: Yeah, you. ",
        "annotations": {
            "express humor": "The speaker uses a humorous tone to respond to the introduction, playfully acknowledging that he is the person being referred to."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): I'm butchering your name. How do you say your name? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the correct pronunciation of a name, which fits the definition of asking a question."
        }
    },
    {
        "utterance": "Iliyan Iliev, WCM, Cornell University: Ilyan. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Ilyan. Okay, sorry. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it's primarily a social interaction and not directly related to the content of discussion or decision-making."
        }
    },
    {
        "utterance": "Iliyan Iliev, WCM, Cornell University: Hi, so uh I'm a associate professor in Wild Cornell Medicine, which is the medical campus of Cornell University here in uh New York City. Uh my lab is immunology lab, but we are very interested in the microbiota and more specifically in the fungal microbiota. Uh so in the area of uh of neuroimmunology, that came in the lab with the observation that uh specific fungi and their metabolites can actually ramp up a signaling which turned out to be through a cytokine called L17 uh and uh the receptor is expressed in neurons and that modulates behavior. So that's some uh direction that we are pursuing right now and we are looking in patients populations how that is working and how polymorphisms and loss of function mutations are affecting those phenotypes. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his position as an associate professor and describes his lab's focus areas, signaling his expertise."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): That's great. We're looking at fungi also on our new treatment, so. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement with Iliyan Iliev's introduction.",
            "signal expertise": "The speaker shares information about her own group's work related to fungi, indicating their expertise in the area."
        }
    },
    {
        "utterance": "Iliyan Iliev, WCM, Cornell University: Oh nice. ",
        "annotations": {
            "supportive response": "Iliyan Iliev is expressing a positive sentiment towards the information shared by Rosa Krajmalnik-Brown, indicating agreement or interest."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Um. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev, WCM, Cornell University: Yeah, we we just had like one study that came up and we are following up on that. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it is a simple statement sharing a research update without explicitly fitting into any of the provided categories."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev, WCM, Cornell University: So it's kind of very interesting. ",
        "annotations": {
            "supportive response": "The speaker expresses a positive sentiment towards the topic of discussion, indicating interest.",
            "express humor": "The utterance could be seen as having a slightly informal tone but does not explicitly make a joke."
        }
    },
    {
        "utterance": "Iliyan Iliev, WCM, Cornell University: and uh pathways that are induced. ",
        "annotations": {
            "develop idea": "The speaker is attempting to elaborate on a previous point by mentioning 'pathways that are induced,' which suggests they are expanding on their research or a study."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Okay, so I'm happy to talk about that later if you want. ",
        "annotations": {
            "encourage participation": "The speaker invites further conversation by expressing willingness to discuss a topic later.",
            "process management": "The speaker manages the conversation flow by suggesting to continue discussing a topic at a later time."
        }
    },
    {
        "utterance": "Iliyan Iliev, WCM, Cornell University: Sure. ",
        "annotations": {
            "Supportive Response": "The speaker is expressing agreement with Rosa Krajmalnik-Brown's offer to discuss something later, indicating a positive and supportive attitude towards the proposal."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): All right, great. ",
        "annotations": {
            "Supportive response": "The utterance 'All right, great' expresses agreement or positive evaluation regarding the introductions or the meeting proceeding."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Um, so Tom. I'm Tom Mansell. I am in uh chemical and biological engineering at Iowa State University. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by introducing the next person.",
            "acknowledge contribution": "The speaker is acknowledging Tom Mansell's introduction and contribution to the discussion."
        }
    },
    {
        "utterance": "Tom Mansell, Iowa State University (he/his): Our interest is in the microbiome as an ecosystem where uh that's that's going to be harsh to our bug of interest, which is a live biotherapeutic. So our goal is to secrete small molecules or peptides or proteins in situ in the gut and in order to do that, obviously it has to thrive in this very competitive environment and be able to do its job, which is secretion of the of the therapeutic. And so we're really interested in we do genome engineering to look at the genes that affect survival phenotypes of these bacteria. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his own expertise and research focus related to the task.",
            "clarify goal": "The speaker defines and clarifies his research objectives and approach."
        }
    },
    {
        "utterance": "Tom Mansell, Iowa State University (he/his): Thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell, Iowa State University (he/his): Uh, Melanie. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Melanie Gareau (UC Davis): Um, I'm Melanie Gareau. I'm an associate professor at the Vet School at UC Davis. Um, and my lab's interested in looking at the development of the microbiota gut brain axis, so how colonization impacts maturation of the gut and how that's reflected in changes in neurodevelopment and behavior in adulthood. Um, I'm a GI physiologist by training and uh we're really interested in how this connects with um pediatric IBD and overall IBD in adulthood. ",
        "annotations": {
            "signal expertise": "Melanie mentions her background as a GI physiologist, signaling her expertise in the field."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): That's great. So I put the question in the, I don't know if you guys see the in the chat. I put the topic for our conversation. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges another group member's input with 'That's great'.",
            "process management": "The speaker is managing the meeting flow by referring to a topic posted in the chat for discussion."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): But before we start taking the conversation, I need someone to volunteer to be a scribe. Can I get someone to volunteer? ",
        "annotations": {
            "ask question": "Rosa Krajmalnik-Brown is requesting a volunteer for a specific task (being a scribe).",
            "encourage participation": "Rosa Krajmalnik-Brown is inviting someone to volunteer, which encourages participation.",
            "process management": "Rosa Krajmalnik-Brown is managing the meeting process by asking for a scribe."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): I can do it. Um, where are we supposed to type notes though? Was there a Google document somewhere or ",
        "annotations": {
            "ask question": "The speaker is requesting information about where to type notes, indicating a need for clarification.",
            "process management": "The speaker is inquiring about the process for note-taking during the meeting."
        }
    },
    {
        "utterance": "Andrew Feig (RCSA (he/him): There is a word doc that if you go into the Google Drive, do you have are you in the Google Drive? ",
        "annotations": {
            "ask question": "The speaker asks if the recipients are in the Google Drive, which is a request for information.",
            "process management": "The speaker is providing information about a document's location, which relates to managing the meeting's or group's process."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): I'm in the Google Drive, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Andrew Feig (RCSA (he/him): Uh, go into the virtual meeting materials. Yep. The the ultimate PowerPoint slide is at the very bottom, Silog MMD 2022 meeting slides. And then there's a raw notes from breakout sessions folder. If you go in there, each breakout session has a raw notes that you you can just freehand just uh We're 1.4. ",
        "annotations": {
            "process management": "The utterance provides instructions on how to access meeting materials, guiding the group on where to find PowerPoint slides and raw notes, which is an act of managing the meeting flow and organization."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): Yep. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): Okay, thanks. All right, I'm I'm good. ",
        "annotations": {
            "acknowledge contribution": "Erin acknowledges Andrew Feig's instructions and confirms her readiness to proceed with the note-taking task."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Barriers affecting the gut brain axis. ",
        "annotations": {
            "clarify goal": "The utterance defines the topic of discussion for the meeting, which is 'Barriers affecting the gut brain axis.'"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): That's the topic. And I just put on the comments box, um, the description of our breakout session and I can. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by confirming the topic and directing participants to the breakout session description."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Hold on one second, I need to close my door. ",
        "annotations": {
            "process management": "The speaker is temporarily pausing the meeting to close their door, which is an action to manage the meeting environment."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): I apologize for that. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by apologizing for a minor interruption, which helps maintain a smooth discussion environment."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): All right, Erin, are you ready? ",
        "annotations": {
            "process management": "This code applies because Rosa Krajmalnik-Brown is managing the meeting flow by ensuring Erin is ready to take notes."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): Yep, I'm I'm good. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Yeah. So we have great expertise in this panel because we have people that are focused on um the chemicals, organoids, the gut, the brain, immunology, so um I I expect great discussion about this. ",
        "annotations": {
            "Supportive response": "The speaker expresses a positive expectation about the discussion, which is a form of agreement or validation.",
            "Encourage participation": "By stating she expects a great discussion, the speaker is encouraging participants to engage."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): So, who wants to get started? ",
        "annotations": {
            "encourage participation": "The speaker is inviting others to contribute to the discussion, encouraging participation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Maybe I should ask the next question. Do you do you think that specific species or secreted metabolites facilitate changes that affect these barriers? ",
        "annotations": {
            "ask question": "The speaker is requesting information on whether specific species or secreted metabolites facilitate changes that affect certain barriers, directly asking a question to the group."
        }
    },
    {
        "utterance": "Faranak Fattahi, UCSF: So I can maybe like start. Um, you know, thinking about the enteric nervous system, um, and how the neurons in the gut regulate the tissue homeostasis, I know they play an important role in uh the the epithelial barrier. And so if you have inflammatory conditions that affect the neurons or in some uh developmental defects if the nerves are not developed properly or the tissue is as they call it aganglionic, the epithelium becomes leaky then that then leads to more inflammation and more damage to the nerves and this cascade perpetual cascade of tissue inflammation and breakdown. Um, I don't really know much about how much has been done in terms of the role of microbiome in this process. If there has been studies any like in in mice or in human patients with germ free versus, you know, antibiotic I don't I don't really know if anything has been done in that space, but I know that there's a lot of cross talk between tissue components there and all of those tissue components could be targeted by microbial factors directly or indirectly. there's a lot to unpack there for sure. ",
        "annotations": {
            "develop idea": "The speaker elaborates on the enteric nervous system's role in tissue homeostasis and its interaction with the epithelial barrier.",
            "ask question": "The speaker inquires about the existence of studies on the microbiome's role in this process.",
            "identify gap": "The speaker identifies a lack of knowledge about the microbiome's impact on the discussed process."
        }
    },
    {
        "utterance": "Iliyan Iliev: So so in humans, there are direct correlations. So we went after some of those genetically, right? So you go actually and you target pathways that are involved in uh in tight junction and uh in pathways that are indirectly actually uh correlated to barriers. And that uh and then if you have actually microbial trigger, you can affect directly the uh blood brain barrier. So uh the question now is uh so so once you come up uh come up with a driver and then a trigger, the question is like uh to what extent it's uh it's really affected and then uh if that will leave lead to uh any physiology. So that's something that we are trying to explore and like how big is that uh change and you can go with different particles and so on, you can figure out uh what size molecules can actually get into the brain, right? Which is important as well. So I I couldn't find I couldn't find very much a lot of work on that. Uh so so we had to design some systems but uh but I'm I'm looking actively to find good work in that area and to kind of follow up uh so if you guys because we are very new, you know, I worked a lot on the gut barrier but not the blood brain barrier. So we are applying a lot of knowledge like that. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing specific pathways, genetic correlations, and the potential impact of microbial triggers on the blood-brain barrier.",
            "identify gap": "The speaker notes a lack of work in the area of how microbial factors affect the blood-brain barrier.",
            "encourage participation": "The speaker does invite others to contribute by mentioning he'd like to find good work in the area and follow up."
        }
    },
    {
        "utterance": "Erin Longbrake: Would the molecule need to be appropriately sized though? I mean, in a sense, if you have inflammatory mediators that are within the bloodstream, they could impact the endothelium and create leakiness that would be independent of the size of the molecule because once you've broken down the barrier then large molecules can pass too. ",
        "annotations": {
            "ask question": "The speaker asks for clarification on whether the molecule needs to be appropriately sized.",
            "develop idea": "The speaker elaborates on the idea that inflammatory mediators can impact the endothelium and create leakiness, independent of the molecule's size."
        }
    },
    {
        "utterance": "Iliyan Iliev: They can, but then uh the other question is uh you know, some of those uh susceptibilities or those uh defects in the barrier you cannot uh really uncover until you have the proper trigger. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a thought or idea previously mentioned, providing further considerations.",
            "identify gap": "The speaker highlights that certain defects or susceptibilities in barriers cannot be uncovered without a proper trigger, indicating a gap in current understanding."
        }
    },
    {
        "utterance": "Iliyan Iliev: So sometimes the trigger is not known. So you have to actually really come up with a system where you predict triggers because if you do it genetically in different mouse models that can be huge enterprise, right? You you it's not a lab, it's kind of a company that has to do it. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea that predicting triggers is complex and requires significant resources, comparing it to a large enterprise.",
            "identify gap": "The speaker highlights a gap in knowledge or approach, specifically the difficulty in predicting triggers without a known trigger."
        }
    },
    {
        "utterance": "Faranak Fattahi: Are there in vitro models that are more scalable for screening through uh molecules that are permeable or unpermeable through the blood brain barrier? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the existence of in vitro models for screening molecules that are permeable or unpermeable through the blood-brain barrier."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, that would be nice, yeah. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or validation for the idea of using in vitro models for screening molecules."
        }
    },
    {
        "utterance": "Faranak Fattahi: Well, I think that's how some pharma companies used to like test drug permeability, so some of those might be useful for microbial metabolites as well. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous idea by suggesting a potential approach for testing microbial metabolites.",
            "offer feedback": "The speaker is providing a suggestion for how to proceed."
        }
    },
    {
        "utterance": "Faranak Fattahi: I'm not sure if any screens in this uh realm has been done before or are the models good enough for these types of studies? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the existence of previous studies or the adequacy of current models, seeking clarification from others."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So Pamela, you work with metabolites and with small molecules. Um any any thoughts about this? ",
        "annotations": {
            "ask question": "The speaker is requesting information or thoughts from Pamela Chang regarding her work with metabolites and small molecules.",
            "encourage participation": "The speaker is directly addressing and inviting Pamela Chang to contribute her expertise or opinions to the discussion."
        }
    },
    {
        "utterance": "Pamela Chang: Yeah, so we I mean in the gut, we look at barrier with uh uh you know, either Caco2 cells that can form a monolayer and then you can give the trigger and then measure flux with fluorescent molecules of different sizes, but I'm actually not familiar with the blood brain barrier either. ",
        "annotations": {
            "develop idea": "Pamela is expanding on her team's research approach to studying gut barriers using Caco2 cells and fluorescent molecules.",
            "identify gap": "Pamela also indirectly identifies a gap in her knowledge regarding the blood-brain barrier."
        }
    },
    {
        "utterance": "Pamela Chang: Iliyan? ",
        "annotations": {
            "encourage participation": "The speaker is inviting Iliyan to contribute to the discussion or share his thoughts."
        }
    },
    {
        "utterance": "Iliyan Iliev: Uh well, the the problem is that you have if you do it through the gut brain axis, you have the intestinal barrier and then the blood brain barrier. So it's very hard to model both in an in vitro system. That's why we went for the in vivo system. So we want to see if an effect in one or two is happening and so on. So that's how we couldn't that's why if there is a system to do that in vitro that will be fantastic. ",
        "annotations": {
            "develop idea": "Iliyan Iliev is expanding on existing ideas and challenges in studying the gut-brain axis, particularly the barriers involved.",
            "identify gap": "He identifies a gap in current research methods, specifically the difficulty in modeling both barriers in vitro.",
            "signal expertise": "Iliyan Iliev states his experience and knowledge in dealing with barriers and modeling."
        }
    },
    {
        "utterance": "Andrew Feig: There's actually an interesting system involving focused ultrasound that you can use to temporarily change the brain uh the CNS barriers. Uh so the blood brain barrier where you can uh the focused ultrasound will cause a temporal gap in the blood brain barrier that allows passage over the span of say 30 seconds and then you can close it again. And so so that would allow you to at least isolate that barrier separate from the intestinal barrier. Um just a thought. ",
        "annotations": {
            "propose new idea": "Andrew Feig introduces a new method involving focused ultrasound to temporarily change the CNS barriers, specifically the blood-brain barrier.",
            "develop idea": "He elaborates on the method of using focused ultrasound, explaining its temporary effects on the blood-brain barrier and its potential applications.",
            "offer feedback": "By suggesting the use of focused ultrasound as a way to isolate the blood-brain barrier from the intestinal barrier, Andrew Feig is offering a specific approach to studying or manipulating these barriers."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, so on the intestinal barrier, I'm trying not to talk too much, but I'm just going to mention quickly that the the the paper that I mentioned by Sarkis Mazmanian and group Sao 2013, one of the things that they show is that they show that the the the gastrointestinal barrier was damage in these mice that had autism like behaviors and that they could repair it with bacterioidis fragilis. They show that with images of the tissue. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by providing more details about a specific study and its findings regarding the gut-brain axis and the effect of bacterioidis fragilis on gastrointestinal barrier damage in mice with autism-like behaviors."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And and also that the metabolites detected were different. The metabolites in the blood were different before and after reparation of this um defect in the barrier. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previously mentioned idea about a study's findings on metabolites in the blood before and after the repair of a gastrointestinal barrier defect."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So I I the the gut the the brain barrier for me also it's distant, like it's hard for me to even think about it, but I feel that the ",
        "annotations": {
            "identify gap": "The speaker expresses a personal difficulty in understanding or relating to the topic of the gut-brain barrier, indicating a gap in their own perspective or engagement."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Iliyan? ",
        "annotations": {
            "encourage participation": "inviting Iliyan Iliev to contribute to the discussion"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, so I know this study, but uh so so with the years, there was an they they they are a few actually molecules that can uh prevent leaky gut. And uh you know, there was this group in Harvard that came with another one as well. So so now now we have molecules where we can modulate that. But uh if it's a genetic defect, how that affects one versus the other barrier and is there a genetic selectivity where that will happen and then basically the microbial or any trigger will affect one versus the other or both. Uh I don't know. I'm I'm putting it very complex here, but uh but those are probably happening simultaneously or in some individuals one is more uh because the the gut barrier you need like epithelial uh integrity and uh in the blood brain barrier you need endothelial integrity as well. So that's where uh you know, the signaling that is uh regulating both uh is different. So the genetic susceptibilities that are affecting one or the other might be different or the same. So how how to put all those factors together uh and then come up with a trigger and model that in order to get to the right model finally. ",
        "annotations": {
            "develop idea": "Iliyan Iliev is expanding on previous discussions about the gut barrier and blood-brain barrier, specifically discussing molecules that can prevent leaky gut and the complexity of genetic defects and triggers affecting these barriers.",
            "ask question": "He poses several questions about the effects of genetic defects on the barriers and the role of triggers."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: What do we know about microbes or metabolites that affect these barriers? ",
        "annotations": {
            "ask question": "The speaker is requesting information about microbes or metabolites that affect these barriers, making this an explicit question to the group."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Maybe others. I don't know if Dave or um Tom or Melanie. I don't mean to put you on the spot, but I want everyone talking. ",
        "annotations": {
            "encourage participation": "Rosa invites specific individuals (Dave, Tom, Melanie) to contribute to the discussion.",
            "process management": "Rosa manages the discussion flow to ensure inclusivity and participation of all members."
        }
    },
    {
        "utterance": "Dave Durgan: No, I don't know much about the metabolites, but one thing that that came to mind in this discussion is and I don't know that there's much done on it, but it's always bothered me is we think so much about the tightness of the blood brain barrier endothelium, but what about in the gut? Um I mean they cross the mucus layer, they cross the epithelium, kind of the last line of defense before being spread systemically is that endothelium in the the gut circulation. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new perspective by suggesting considering the gut's endothelium.",
            "develop idea": "The speaker elaborates on the idea by providing context and considerations about the gut's endothelium."
        }
    },
    {
        "utterance": "Melanie Gareau: So if I can go back to the metabolites, I know that we we use using chambers to study intestinal physiology, so we can look at ion transport and permeability in pretty good detail. And if you provide short chain fatty acids for example, you can improve or disrupted barriers. So metabolites can play a role. Um with respect to the correlation versus association, the best one that I know of is IBD where you can measure permeability defects in patients before they become IBD patients if you'll do a screen. So it suggests that permeability is one of the initiating factors, whether that's caused by microbiome changes is unknown at the time right now, but certainly genetic susceptibility is correlated with that. So now we're trying to put together genetics, permeability, microbiome and that I don't think that's still resolved right yet, but ",
        "annotations": {
            "develop idea": "Melanie Gareau is expanding on the idea of how metabolites, specifically short-chain fatty acids, can improve or disrupt barriers in intestinal physiology, and discussing its implications in IBD."
        }
    },
    {
        "utterance": "Melanie Gareau: the other thing that we haven't mentioned is um whether things get in through permeability and then a second hit like stress is the one that breaks the central barrier for example because we know that stress can impact the endothelial barrier in the brain and and modulate blood brain barrier function. So um I think there's still a lot of black boxes in all this, but um certainly you can sometimes decouple those two. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by suggesting that stress could be a second hit that affects the central barrier.",
            "ask question": "The speaker implies a need to consider an additional factor (stress) that could affect the barriers, encouraging further discussion."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: What do you think, Tom? ",
        "annotations": {
            "encourage participation": "The speaker is directly asking Tom to contribute his thoughts or opinions to the discussion.",
            "ask question": "The speaker is requesting information or thoughts from Tom."
        }
    },
    {
        "utterance": "Tom Mansell: So I'm I'm a bacteria person and the host aspect is is is not my area of expertise, but I do know that there are probiotics that if you when administered, they do create better tight junctions, right? So E coli Nissle is an example um of uh a probiotic that um one of its functions of course is to is is niche defense because it's very similar to Shigella and uh Salmonella, but um uh another thing that that's been found is in in these kind of monolayer type studies, right? Not I don't know about in vivo right now, but um you you find increased tight junction formation just from the administration of this this E coli Nissle. Um and so the ",
        "annotations": {
            "identify gap": "The speaker explicitly states their lack of expertise in the host aspect.",
            "develop idea": "The speaker is expanding on existing ideas about probiotics, specifically E coli Nissle, and their effect on tight junctions."
        }
    },
    {
        "utterance": "Tom Mansell: mechanism of that is not not yet known, but I think in in general, what what I would like to understand is um what is the host? So there's, you know, we monitor these things with what E cadherin uh and and other gene expression, right? So um but the actual barrier between cells is uh a sort of mostly protein, mostly extracellular matrix type material, like what is the downstream effect? Like what what we're talking about so far is like what signaling leads to this phenotype, right? But is it is there something about like um the the protein or carbohydrate makeup or availability of those things that may um that may contribute to that and you know, that's that's just I I think about things a lot of molecular level. So that's that's kind of where I'm sort of coming from here and so if anybody can enlighten me in that respect, that would be great. ",
        "annotations": {
            "Ask question": "The speaker is requesting information about the host and the barrier's composition, indicating a need for clarification.",
            "Identify gap": "The speaker identifies a gap in knowledge regarding the molecular level effects and the composition of the barrier.",
            "Encourage participation": "The speaker invites others to enlighten him, encouraging participation."
        }
    },
    {
        "utterance": "Faranak Fattahi: Are you thinking that some of those components could be affected by the microbiome as well? Like it could be directly secreted by them or expressing those proteins in the host could be altered by factors from the microbiome? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on whether certain components could be affected by the microbiome, directly or indirectly."
        }
    },
    {
        "utterance": "Tom Mansell: Right, so that could be a possible explanation for why short chain fatty acids would do that for example, right? Um as histone deacetylase inhibitors. ",
        "annotations": {
            "develop idea": "Tom Mansell is expanding on an existing idea by suggesting a possible explanation for how short-chain fatty acids work.",
            "offer feedback": "Tom Mansell is providing a specific suggestion for understanding the mechanism of short-chain fatty acids, which serves as feedback on the discussion."
        }
    },
    {
        "utterance": "Tom Mansell: Um but yeah, I'm I'm really thinking more about the physical makeup of the barrier. ",
        "annotations": {
            "develop idea": "Tom Mansell is expanding on previous discussions by focusing on the physical makeup of the barrier."
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it's a minimal response and doesn't explicitly fit into any other category."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: there. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: I wonder if there are particular I wonder if there are particular for example limiting limiting carbohydrates or limiting amino acids, right? If it's all collagen or you know, ",
        "annotations": {
            "Ask question": "Tom Mansell is requesting information or clarification on specific factors that might influence the barriers.",
            "Propose new idea": "Tom Mansell is suggesting considering specific factors (carbohydrates, amino acids) that could be relevant to their discussion."
        }
    },
    {
        "utterance": "Tom Mansell: arginine. ",
        "annotations": {
            "None": "No relevant code explicitly applies to this utterance as it stands, but it could be argued to implicitly relate to developing ideas if considering the mention of a specific amino acid in the context of barrier composition."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: I understand like that, you know, ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Um ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: is that something that that we can that we can map back by by metabolomics? ",
        "annotations": {
            "ask question": "The speaker is explicitly requesting information about the feasibility of using metabolomics to map back certain changes."
        }
    },
    {
        "utterance": "Iliyan Iliev: And it's probably worth also thinking that sorry, where are you? Erin, where are you? ",
        "annotations": {
            "ask question": "The speaker is requesting information about Erin's location.",
            "encourage participation": "The speaker is inviting Erin to contribute by asking where she is."
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, I was just going to say that something that seems like could be a question that could be studied in an in vitro model system. ",
        "annotations": {
            "None": "No relevant code perfectly applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: I don't know the answer though, but it seems like a question that would be amenable to in vitro studies. ",
        "annotations": {
            "develop idea": "Erin is expanding the discussion by suggesting that the question could be studied using in vitro studies, thereby developing the idea of how to approach the topic."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Sorry, the internet kicked me out and it took me a while to be able to get back in. So I hope you guys were doing great without your moderator. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Just me talking, so no. ",
        "annotations": {
            "express humor": "The speaker makes a joke about their own talking, showing a lighthearted and humorous tone."
        }
    },
    {
        "utterance": "Faranak Fattahi: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Dave, I think you were going to say something there. Sorry. Oh, I was just going to bring up a more direct interaction not necessarily metabolites, but active things like proteases like ginger panes and things that can uh at least from the oral bacteria uh have been shown to both break down the epithelium as well as the endothelial barrier uh in brain. Um so that's more of a a direct protease route which has been shown to have effects at both sites. ",
        "annotations": {
            "propose new idea": "Iliyan Iliev introduces a new idea about the role of proteases from oral bacteria in affecting barriers in the brain.",
            "develop idea": "He elaborates on the idea by providing specific examples of proteases and their effects on the epithelium and endothelial barrier.",
            "acknowledge contribution": "Iliyan Iliev acknowledges Dave's potential contribution by mentioning that Dave might have something to say."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah. So in the gut um um Iliyan, I don't know if you looked at proteases and fungi because that might be important also. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on whether Iliyan has considered proteases and fungi in his work."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, we do. We do. We actually have few candidates that that we discovered with uh yeah, human uh human uh antibody assays. Uh and they they are few proteases that are uh you know, that are involved but uh I'm not sure at what level because there are two ways how the barrier, at least two ways, right? How the barrier might be impaired. It can be directly through, you know, tight junction defects and then uh you know, external factors that are uh that are basically aggravating those phenotypes. But then the other problem is actually reparative problems. So those are like very long term uh you know, ",
        "annotations": {
            "develop idea": "The speaker is expanding on their research findings and ideas regarding proteases and barrier impairment, providing details on mechanisms and factors involved."
        }
    },
    {
        "utterance": "Iliyan Iliev: you know, processes and they can be taking part in specific areas of the intestine. So it's different from the cellular and both of those have similar effect of increased permeability. So so so that's how it's very complicated, right? There there is so much uh to do on that side, but uh but you know, those two different levels of complication a bit mess up uh the screening approaches because if you start looking at tight junctions, you can set up an in vitro platform and do some part of that with the caveat you don't have immune system then, which is very important for this process of basically bringing up the tight junctions. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas about the complexity of intestinal processes and their impact on permeability.",
            "offer feedback": "The speaker is providing insights into the challenges of studying these processes, particularly regarding the immune system's role and the limitations of in vitro platforms."
        }
    },
    {
        "utterance": "Erin Longbrake: That's a good point though. Um so it sounds and going back to the original question, it sounds plausible that certain microbes um either make small metabolites that impact the barrier or make proteases that impact components of the barrier. But certainly immune cells also impact immune cells which are in the mucosal layers and certainly immune cells have a number of ways to bypass barriers um to migrate into both the brain and other parts of the body to make active metabolites and so you know that one question could be whether the it's a direct effect of um microbes and microbial products or whether the immune cells serve as a as a mediator. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas about the interaction of microbes and immune cells with body barriers.",
            "ask question": "The speaker poses a question about the direct effects of microbes versus the mediating role of immune cells."
        }
    },
    {
        "utterance": "Iliyan Iliev: And there is one more component actually, toxins. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the existing discussion about factors affecting barriers by mentioning toxins."
        }
    },
    {
        "utterance": "Iliyan Iliev: So we just had a study uh there is a fungal toxin that is basically directly uh uh lytic to epithelial cells and microphages underneath. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new study about a fungal toxin affecting epithelial cells and microphages.",
            "signal expertise": "The speaker shares specific knowledge from a study, indicating expertise in the area."
        }
    },
    {
        "utterance": "Iliyan Iliev: And so that is messing up the system a lot and that's not a protease. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous point by providing more specific information about the nature of a factor affecting the system, clarifying that it is not a protease."
        }
    },
    {
        "utterance": "Iliyan Iliev: Uh ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: So so so that was something very surprising. So those also can play a role depends on the concentrations and where they're released. And so how did you how did you find these toxins? Because you were doing promics and you found this instead of a protease? ",
        "annotations": {
            "develop idea": "The speaker is elaborating on a previous point about toxins and their effects.",
            "ask question": "The speaker asks a question about how certain toxins were discovered."
        }
    },
    {
        "utterance": "Iliyan Iliev: No, it's a huge study. So we started differently. So we first looked at uh patients with IBD where we were looking for specific fungi. So we found actually fungi that are enriched in those specific patients and from there we wanted to see uh if there is any correlation with uh enrichment of those fungi and the disease. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on their research approach and findings.",
            "signal expertise": "The speaker is demonstrating their knowledge in the area of study, specifically regarding research on IBD and fungal correlations."
        }
    },
    {
        "utterance": "Iliyan Iliev: economics and number of different platforms in vitro and that's where actually all those strains it was a lot of work. So a lot of strains basically split by their ability to damage epithelium or not and they are the same species. So from there we basically took over what is the reason and that's why we went for all the proteases but it wasn't that and then in the genome we found actually this fragment which is responsible for activation of toxin that is process extreme severely. So so anyway and that toxin though is super potent and it's actually released in the patients and it correlates with patients that have severe disease they care carry the strains that produce the toxin. So so it's it didn't go with the screening in the beginning. ",
        "annotations": {
            "develop idea": "The speaker is expanding on their research process and findings related to strains and their effects on epithelium and toxin production."
        }
    },
    {
        "utterance": "Iliyan Iliev: Uh yeah, I'm looking always for ways to actually do the screening first but it never if you mess up the screening platform then you actually lose a lot of information and and you lose something that might be actually there. So that's where it's always a constant battle who it does. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the challenges of screening in research, providing insight into the process and the importance of not missing crucial information."
        }
    },
    {
        "utterance": "Dave Durgan: So Aaron's comment on the the link via the uh immune system kind of brought something to mind. There's been some increased interest lately in terms of uh the inflammatory response originating from the meninges and then migrating into the brain. Um as we've looked at stroke models more closely, it's not just inflammation in the parenchyma but uh it seems like a a large portion of those immune cells are coming from from the meninges and uh it's one of these areas where there's fenestrated uh on the Venus side so it's one of these areas that are very open uh to potentially either metabolites or to uh endotoxins things like that coming from uh from the gut. And there there's just some really interesting observations there. For instance, if you get inflammation and upregulation of IGA in the gut, it also corresponds with increased IGA production uh in the dural layer. Um so it's kind of this co-evolutionary idea that it's it's in the benefit of the organism to if something gets across the epithelial barrier to also be able to recognize that at the brain um and respond in a very rapid way whether that be uh plasma cells which are migrating sensitize in the gut and then migrating into these these areas in the meninges that then have pretty free access to get across to the brain. So kind of an interesting idea. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement and builds upon previous contributions without adding new content.",
            "encourage participation": "The speaker invites further discussion by sharing observations and asking implicitly for others' thoughts.",
            "clarify goal": "The speaker is guiding the discussion towards understanding interactions between the gut, brain, and immune system."
        }
    },
    {
        "utterance": "Iliyan Iliev: But what's the antigen there? That's very interesting and I I looked at those studies. But what's the antigen in the brain that will activate the plasma cell to keep excreting those IGAs or it's a passive process. ",
        "annotations": {
            "ask question": "The speaker is seeking clarification on the antigen in the brain that activates plasma cells, directly asking for information.",
            "develop idea": "The speaker is expanding on the discussion about the gut-brain axis by inquiring about specifics of antigen activation of plasma cells."
        }
    },
    {
        "utterance": "Dave Durgan: Well, the I mean the antigens could be coming from either direction, either from there there's circulation to the meninges and on the Venus side that's where it's highly fenestrated. So you can have antigens from gut entering circulation and then sensitizing these cells in the meninges or you can have like in the case of stroke or brain damage, you can have antigens coming from the parenchyma as well uh across the meninges and setting off the immune cascade there. ",
        "annotations": {
            "develop idea": "The speaker expands on an idea about the potential sources of antigens that could influence the brain through the meninges."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, so the migration of IGA plasma blast from the gut going far away it's very hard to track. We worked a lot on IGA and uh I kind of limit the work actually to the gut because it was very hard to really because IGA plasma blasts are different and they produce uh you know just monomeric IGA if you if you have antigen going actually systemic and and uh and uh priming them. So that's where I don't know what what uh what is the way to track them from the gut to the brain. ",
        "annotations": {
            "identify gap": "The speaker identifies a gap in knowledge or methodology regarding tracking IGA plasma blasts from the gut to the brain.",
            "ask question": "The speaker asks for input or suggestions on how to track IGA plasma blasts from the gut to the brain.",
            "encourage participation": "The speaker encourages others to contribute by asking for their thoughts or solutions."
        }
    },
    {
        "utterance": "Dave Durgan: Um all that I can say to that I guess is the evidence that that I'm familiar with is so in the same animal they've uh done B cell receptor sequencing in the in the gut as well as in these areas in the meninges and shown that there's uh very high similarity or co-occurrence of the same receptor uh in both sites that statistically shouldn't be occurring um unless these plasma cells were actually migrating uh from gut to to these meningial areas. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by providing specific evidence related to the migration of plasma cells from the gut to the meninges.",
            "supportive response": "The speaker's statement is supportive of the ongoing discussion, providing evidence for the concepts being discussed."
        }
    },
    {
        "utterance": "Faranak Fattahi: I have a unrelated question. Um so from the standpoint of developing models that would help the field, um where do you think are like do we have some good ideas around what factors could be triggering the leaky bear like the leaking from barriers and we're just trying to drill down on the mechanisms of how that happens or are we in the phase where we're like we should be screening for a larger set of molecules or metabolites or factors that could be coming from the microbiome. I'm trying to think if we need some sort of scalable model in order to search for more of those or models that would help us like you know interrogate specific things mechanistically on a more complex level. Uh maybe the answer is both so I'd love to hear from all of you at that. ",
        "annotations": {
            "ask question": "The speaker requests information on developing models to understand barrier leakage and whether they should be screening for a larger set of molecules or metabolites.",
            "encourage participation": "The speaker invites others to share their thoughts, indicating a desire for input from the group."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Don't all speak at the same time. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by asking participants not to speak at the same time."
        }
    },
    {
        "utterance": "Tom Mansell: Well, if if we're talking about metabolites, you know, generally we think about metabolites as as organic molecules, right? But a lot of proteases um are are metal dependent, right? So are there bacteria that are I I know for example, um E coli Nissle is um heightens that niche defense because it has a tons of iron transporters. Basically sucks up all of the iron. And so other organism which is limiting so other organisms are not allowed to use it. Um but zinc and calcium and other, you know, cat ions are often a part of these metallo or matrix metallo proteases. Um and so one like even lower than the sort of organic metabolite level is like what's the ion composition um there and is that something that could provide as as as Faranak said, uh a more mechanistic understanding. ",
        "annotations": {
            "ask question": "The speaker asks a question about the existence of bacteria with specific iron transport mechanisms.",
            "develop idea": "The speaker is expanding on previous ideas by discussing the role of ion composition in protease function and its implications."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And so would you think that these inorganic chemicals um enhance gut permeability or decrease gut permeability. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the effects of inorganic chemicals on gut permeability.",
            "encourage participation": "The question invites others to contribute their thoughts or expertise."
        }
    },
    {
        "utterance": "Tom Mansell: Well, if they're if they're yeah. ",
        "annotations": {
            "None": "The utterance is a brief acknowledgment without adding new content to the discussion."
        }
    },
    {
        "utterance": "Tom Mansell: Sorry, if they're required co-factors for the enzymes of interest then yes, their presence might affect the overall enzymatic activity. Um I don't know though, right? I don't know what the KDs for these things are, what the actual physiological amounts are, but I know that bacteria manipulate their environment by grabbing enzyme uh grabbing ions. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the existing idea about microbial effects on barriers by discussing the role of ions as co-factors for enzymes, which could affect enzymatic activity."
        }
    },
    {
        "utterance": "Tom Mansell: Anybody has for expert? ",
        "annotations": {
            "ask question": "Tom Mansell is requesting information on if there is an expert present."
        }
    },
    {
        "utterance": "Tom Mansell: those toxins can be proteases, right? So ",
        "annotations": {
            "ask question": "The speaker is seeking confirmation or agreement with a questioning tone at the end of the statement."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, well, some of them, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: So to go back to Faranak's question, like what would be a model system to figure out if and how bacteria microbes impact, let's just stick with a gut epithelial barrier, um, to start with. you know, barrier function in general. ",
        "annotations": {
            "ask question": "The utterance explicitly asks for a model system to study the impact of bacteria/microbes on the gut epithelial barrier.",
            "develop idea": "It builds upon the existing discussion about the interaction between microbes, their metabolites, and biological barriers."
        }
    },
    {
        "utterance": "Erin Longbrake: I mean it seems to me like this starts with in vitro experiments with iterative culture systems. Like you know, you have bacteria, you mix bacteria, you you know, and you simplify. That gets a little more complicated because not all bacteria live nicely in culture systems. Um, you could also do it with supernates and then try to fractionate the supernates from gut. Um, but again, um, this seems like an iterative screening process where you have a model system and you iteratively just screen. ",
        "annotations": {
            "propose new idea": "Erin suggests a new methodological approach using in vitro experiments with iterative culture systems to study the impact of bacteria on barriers.",
            "develop idea": "Erin elaborates on her proposed method by discussing specifics such as using bacteria, supernates, and fractionation."
        }
    },
    {
        "utterance": "Faranak Fattahi: focus on a just general phenotype of like, you know, barrier permeability, um, and you know, integrity of the epithelial barrier and just look to just isolate any sort of supernate or bacterial species that impact that barrier in one way or another. And then from there try to pin it down in terms of like what the factors are and what the mechanisms are and how they affect the epithelial cells or other tissue components. You could like imagine multiple layers of in vitro models. You can have a very simple model with just epithelium or like more complex models of gut organoids and then you can have the nerves being there or the immune cells being there and like validation layers and then eventually translate all this to mice. ",
        "annotations": {
            "propose new idea": "The speaker proposes a structured research approach to study the impact of microbiome components on barrier permeability and integrity.",
            "develop idea": "The speaker expands on the proposed research approach, detailing steps such as isolating supernates or bacterial species and using in vitro models.",
            "clarify goal": "The speaker clarifies the goal of the research, which is to understand the effects of microbiome components on epithelial barrier permeability and integrity."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I have not heard much and maybe you guys talked about it when I when I got kicked out about mucose and the mucosal, you know, membrane because that's important too. And that's a source of interaction with microbes. Any comments, thoughts? ",
        "annotations": {
            "propose new idea": "The speaker introduces a new topic of mucose and the mucosal membrane as a source of interaction with microbes.",
            "ask question": "The speaker requests comments or thoughts from the group, seeking information or opinions."
        }
    },
    {
        "utterance": "Faranak Fattahi: I mean, would some of these same proteases be involved in mucosal disintegration or like are there ways that microbes could trigger higher production of mucus or is that like, you know, worse for their own survival? I'm not sure just like I don't really know much about the like microbe mucus production cycle if that's something there's much known about that or not. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the role of proteases in mucosal disintegration and how microbes could influence mucus production.",
            "identify gap": "The speaker is recognizing a gap in their knowledge about the microbe-mucus production cycle."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's really important, I think. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement with a previous statement, showing a positive evaluation without adding new content."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, so there there are mucinolytic bacteria and acrimancia and uh, uspirilum are very good examples. The and you know, like uh, fungi that we study, some of them are actually present in the mucus. That's how we figure out actually that they're important for the barrier function. Uh, so so uh, we still try to figure out if they utilize the mucus as uh, as a source or they're there for other reasons. But for the mucinolytic bacteria it's figured out and the enzymes are isolated. So that's uh, that that's some cool science that has been done there. I I really liked, you know, the studies from uh, uh, Gunner's lab. I heard he's going to be uh, probably, you know, in five years retiring or something, but uh, they they were like really eye opening uh, when I saw them. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of how certain bacteria and fungi interact with mucus.",
            "signal expertise": "The speaker demonstrates his knowledge by mentioning specific bacteria and referencing studies.",
            "acknowledge contribution": "The speaker acknowledges the work of Gunner's lab."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Who's lab? ",
        "annotations": {
            "ask question": "The speaker is requesting information about a specific lab mentioned in the conversation, indicating a need for clarification or further details."
        }
    },
    {
        "utterance": "Iliyan Iliev: Gunnar Hanson. He's in uh Sweden. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Do you want you know the name or maybe you can put it in the chat? ",
        "annotations": {
            "ask question": "The speaker is requesting information about sharing a name, possibly through a chat, which directly falls under asking for information or clarification."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. Yes. He's uh I think you spell it like that or something here. Let me see. Uh Thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: So one of the things that got brought up at last year's dialogue meeting was we had there was a bunch of like um engineers who were making things that you ate that went and sampled your gut at multiple locations on all the way down. I almost think that something like this if you could if you could um have that kind of a technological probe that samples mucosal if you will or kind of adherent bacteria, um that then you could do sequencing on and kind of target your in vitro screening models to the bugs that you now know are stuck to the mucosa, maybe that would be a way to narrow things down a little bit from the entire gut microbiome. I'm not a chemist or an engineer in any way, but that was something that was brought up a bunch last year. ",
        "annotations": {
            "propose new idea": "introducing a new approach or method for studying the gut microbiome by suggesting the use of a technological probe to sample mucosal or adherent bacteria",
            "develop idea": "building upon a previously discussed idea from last year's dialogue meeting about using technology to study the gut microbiome"
        }
    },
    {
        "utterance": "Iliyan Iliev: No, it's uh it's actually exists. That how we found the mucosa associated fungi. So basically all the patients that come for colonoscopy, they go on cleansing. So they're clean uh relatively clean and then you go with a scope and you can actually go against the wall and wash from there and take that part. and that's where we did the sequencing and that's how we found what's associated with the mucosa. But uh in humans it's very hard otherwise. If you go with a probe, it's not going to go in the mucosa and sample clean because it will go goes after that in the fecal material. But in mice you can do a lot of cool stuff though. ",
        "annotations": {
            "develop idea": "The speaker explains a method for sampling mucosa-associated fungi during colonoscopy, detailing the process of cleansing, using a scope to collect samples, and sequencing to identify associated fungi.",
            "signal expertise": "The speaker demonstrates expertise in microbiology research methods, specifically in sampling and sequencing fungi associated with the mucosa.",
            "identify gap": "The speaker notes a challenge in human research, stating 'in humans it's very hard otherwise' to sample the mucosa cleanly compared to mice."
        }
    },
    {
        "utterance": "Iliyan Iliev: But again, I Gunnar Hanson, he has like great stuff on uh on uh, you know, sampling actually mucus. It's more like in mouse systems, but uh it's uh it's really eye opening studies at that time. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges Gunnar Hanson's contribution to the field, specifically mentioning his work on sampling mucus."
        }
    },
    {
        "utterance": "Tom Mansell: that there are on a carbohydrate level, there are some carbohydrate substrates that can be modified uh in um azide groups. So if you have a particular, for example, an O glycan that would be a substrate for a mucinophilic bacteria. Um, it's possible that you could synthesize and one of those moieties with a click um substrate on it. So the azide group which enables click chemistry or start ligation which would you could then click on a fluorescent probe uh too, right? So um you could you know, those bacteria that are utilizing these things might break it down and then incorporate that into their um you know, proteoglycan and then you would have clickable bacteria that would these would be the bacteria that are able to eat um moieties that are found in the mucus. So that might you could possibly use that as a proxy for um those guys uh and and identifying probably with you know, a little broader identification of those things that are that are able to perform these mucolytic events, but that not might not be exactly what we're looking for here. But there are chemical probes like that where you can you feed a sugar that has an azide group and then it it's displayed on the bacterium. And probably the host too. ",
        "annotations": {
            "propose new idea": "Tom Mansell introduces a new approach for studying bacterial interactions with mucus, suggesting the use of chemical probes with azide groups to track bacteria that can utilize mucus components.",
            "develop idea": "He elaborates on the potential application of this approach, explaining how it could be used to identify bacteria that perform mucolytic events."
        }
    },
    {
        "utterance": "Pamela Chang: Sorry, so I was a PhD student in Carolyn's lab and that was part of my PhD. ",
        "annotations": {
            "signal expertise": "Pamela Chang is explicitly stating her academic background as a PhD student in Carolyn's lab, which relates to her expertise."
        }
    },
    {
        "utterance": "Tom Mansell: Oh, so you're all set. ",
        "annotations": {
            "supportive response": "This code applies because the utterance acknowledges and confirms a previous statement, showing agreement or understanding without adding new content."
        }
    },
    {
        "utterance": "Pamela Chang: Oh great. ",
        "annotations": {
            "Supportive response": "The utterance expresses a positive sentiment towards a previous statement, indicating agreement or approval."
        }
    },
    {
        "utterance": "Iliyan Iliev: Fantastic. ",
        "annotations": {
            "supportive response": "The speaker is expressing a positive evaluation or agreement with a previous statement or idea."
        }
    },
    {
        "utterance": "Pamela Chang: So ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Pamela Chang: So actually since I left the lab uh ",
        "annotations": {
            "signal expertise": "Pamela Chang explicitly states her past experience in a lab, signaling her expertise."
        }
    },
    {
        "utterance": "Pamela Chang: the number of studies have come out from other groups that have been able to do that in vivo labeling in in a mouse. ",
        "annotations": {
            "acknowledge contribution": "Pamela Chang is verbally recognizing another group's input, specifically mentioning that other groups have been able to do in vivo labeling in mice."
        }
    },
    {
        "utterance": "Pamela Chang: Um, and in some cases they can even do the click chemistry in vivo too. Uh if you're interested, I can send you send you some uh some of those papers, but but yeah, I'm not necessarily pursuing that myself in my own lab. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it primarily involves an offer to share papers, which doesn't fit neatly into the provided categories."
        }
    },
    {
        "utterance": "Tom Mansell: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance or it is too brief to apply another code"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: highlights and see what we're going to report. Um, so I'm I'm I'm happy to let you know in like 10 or 15 minutes, but I just wanted to bring to your attention that maybe um if there's something you really wanted to say and you haven't brought it up, maybe this is a good time. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by indicating when they will report back and suggesting a time for others to contribute.",
            "encourage participation": "The speaker is inviting participants to share any thoughts or comments they might have, encouraging active participation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Any other thoughts that you had maybe before we started even the discussion. ",
        "annotations": {
            "encourage participation": "The speaker is inviting others in the group to contribute their expertise, opinions, or ideas."
        }
    },
    {
        "utterance": "Faranak Fattahi: No specific thoughts, but I do have a question. I I wondered if Melanie could tell us a little bit more about the assays you do to measure epithelial barrier. You talked about um using chambers and um so how high throughput are they and like can you like, you know, test a hundred things or is it like only a matter of a few things that you'd be validating. ",
        "annotations": {
            "code name": "signal expertise",
            "explanation": "The question is directed at Melanie, indicating that her expertise or previous statements are being sought."
        }
    },
    {
        "utterance": "Faranak Fattahi: You're just trying to get a sense of how good the models and assays are in the field and to pay more attention to assay development and those areas. ",
        "annotations": {
            "identify gap": "The speaker recognizes the need for better models and assays in the field, indicating a gap in current research capabilities."
        }
    },
    {
        "utterance": "Melanie Gareau: Sure. Um, so using chambers are great at getting lots of information on not so many samples. Um, so they're not very high throughput. We have eight right now um to do a fitzy assay. It's a two hour assay, so you can only do eight times two, maybe three in a day, so it's low throughput. Um, but you get a lot of information. ",
        "annotations": {
            "develop idea": "Melanie is expanding on the idea of using chambers in research, providing more details about their capabilities and limitations.",
            "signal expertise": "Melanie explicitly states her experience with using chambers, indicating her expertise in this area."
        }
    },
    {
        "utterance": "Melanie Gareau: Um, so that's one of the big problems. We can put organoids on them, so we don't we haven't done it yet, but I know that you can. So you can put inserts in in there. Um, there so you you can get more information than for example, um TER for um kick or something like that. ",
        "annotations": {
            "develop idea": "Melanie is expanding on existing ideas by suggesting the use of organoids and inserts in experimental setups.",
            "offer feedback": "Melanie provides a suggestion for improving experimental approaches by comparing the use of organoids/inserts to TER measurement.",
            "identify gap": "Melanie mentions a problem or limitation, indicating an area for improvement in their current experimental capabilities."
        }
    },
    {
        "utterance": "Melanie Gareau: Um, so so and we can also do in vitro stimulation. So you can you can put molecules in there, watch them transport across or see how they interact and generate or change ion transport or permeability. So we have done that as well. Um, it it's the throughput problem. So you really need to know what you're you have to narrow it down um before you set it up. So the the only thing we can do is potentially four tissues from one animal and so you can do sequential, so you can try four different treatments on one tissue, for example. ",
        "annotations": {
            "develop idea": "Melanie is expanding on the idea of using in vitro stimulation and chambers to study epithelial barrier function.",
            "identify gap": "Melanie points out the limitation of their method, which is the throughput problem and the limited number of tissues that can be used from one animal.",
            "offer feedback": "Melanie provides insights into the practical application and limitations of in vitro stimulation."
        }
    },
    {
        "utterance": "Faranak Fattahi: Are there like markers? I'm thinking if there are if you have like a section of the epithelium or just like an epithelial monolayer culture, are there proxies or markers that correlate with epithelial integrity that you could use for a higher throughput, maybe image based analysis or some other indirect way of correlating that with barrier integrity to then first test a wide net and then narrow things down for these more sophisticated measurements. ",
        "annotations": {
            "ask question": "The speaker is asking a question about the existence of markers for epithelial integrity that could be used for higher throughput analysis.",
            "identify gap": "The speaker is also implicitly identifying a gap in current methodologies for assessing epithelial integrity, specifically in terms of throughput."
        }
    },
    {
        "utterance": "Melanie Gareau: Not a reliable one that I could think of. Um, I'd have to maybe go back and look a little bit more closely, but to my knowledge there isn't one really reliable factor. There's a few that have kind of come up and then were kind of disregarded. ",
        "annotations": {
            "identify gap": "Melanie Gareau is highlighting a gap in knowledge regarding reliable factors for assessing epithelial integrity."
        }
    },
    {
        "utterance": "Melanie Gareau: Um, I think there's more a lot of movement towards uh co culture systems with um more engineering involved where you have small wells that are separating cells um to kind of create gut brain models that way. So I that's not something that I know much about, but that's certainly where people are going with um collaborating epithelial physiologist collaborating with um. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Melanie Gareau: Engineers and things like that. So there I know there's a lot of people that are creating uh in vitro compartmentalized systems where you can compare those things. Those would be higher throughput. ",
        "annotations": {
            "supportive response": "The speaker is expressing a positive view on the development of in vitro compartmentalized systems.",
            "develop idea": "The speaker is expanding on the concept of using in vitro compartmentalized systems for comparisons."
        }
    },
    {
        "utterance": "Faranak Fattahi: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Melanie, would you mind putting the name of this uh device in the chat? I'd um go ahead so I know how to spell it. ",
        "annotations": {
            "process management": "Tom Mansell is asking Melanie to provide the name of a device via the chat to facilitate communication and understanding within the meeting."
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, I caught chambers, but not. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Yeah, yeah, okay, great. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or positive evaluation with phrases like 'Yeah, yeah, okay, great.'"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So what I'm hearing from you Melanie is that um these are great to test specific hypothesis, which is what you do with a lower throughput system. You know, I think people that think about higher throughput system is more to do stuff that I would say it's maybe more exploratory um, which is great, you know, to generate hypothesis, but it sounds like your systems are good to test specific hypothesis. Is that am I hearing that right? ",
        "annotations": {
            "summarize conversation": "Rosa Krajmalnik-Brown is summarizing her understanding of Melanie's points about experimental systems.",
            "ask question": "Rosa Krajmalnik-Brown asks for confirmation on her understanding."
        }
    },
    {
        "utterance": "Melanie Gareau: Yes. ",
        "annotations": {
            "None": "The utterance is a brief acknowledgment without adding new content or engaging in discussion."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Any other thoughts or do we want to go through our summaries so we can all make sure that um. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by asking if there are any other thoughts before proceeding to summaries."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Your contributions are all there. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and validation of someone's contributions, providing a positive acknowledgment."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: You know, do you want to share, Erin? I hope you can share. ",
        "annotations": {
            "encourage participation": "The speaker invites Erin to contribute her thoughts or ideas, encouraging her participation in the discussion."
        }
    },
    {
        "utterance": "Erin Longbrake: Um. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Well, it looks like I can. Give me one second to find the right window. Okay, here we go. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: [screenshare] ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: See, this is how they want us to share it because last year they actually had a a slide, a PowerPoint slide. ",
        "annotations": {
            "process management": "The speaker is discussing the method of sharing a PowerPoint slide, relating to managing the meeting or discussion process."
        }
    },
    {
        "utterance": "Faranak Fattahi: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Faranak Fattahi: I think we need to copy these over to the PowerPoint doc. ",
        "annotations": {
            "assign task": "The speaker is suggesting an action item for someone to copy information to a PowerPoint document."
        }
    },
    {
        "utterance": "Erin Longbrake: I think it's also on the same Google Drive. ",
        "annotations": {
            "acknowledge contribution": "Erin is acknowledging and building on a previous contribution regarding sharing information.",
            "supportive response": "Erin's statement is supportive as she provides helpful information about the document's location."
        }
    },
    {
        "utterance": "Okay.: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, that one. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging a previous contribution or suggestion, showing they are engaged and following the discussion."
        }
    },
    {
        "utterance": "Erin Longbrake: [screenshare off] ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): That's good. ",
        "annotations": {
            "Supportive response": "The speaker expresses a positive sentiment towards a previous statement, indicating agreement or approval."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): I just have to recapitulated again. Hold on. Why is this doing weird? Hold on. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: We spoke a little bit about the blood brain barrier in the beginning, not too much. We focus more on the on the gut. ",
        "annotations": {
            "summarize conversation": "The speaker summarizes the conversation that has taken place, mentioning the discussion of the blood-brain barrier and the focus on the gut."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): Speak up if I'm missing something or if there's better ways to do this. ",
        "annotations": {
            "encourage participation": "Inviting others to contribute their expertise or opinions.",
            "ask question": "Requesting information or input from other group members."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: The immune system also was mentioned as one of the um interactive um ",
        "annotations": {
            "summarize conversation": "The speaker summarizes or refers back to a previously discussed topic, specifically mentioning the immune system as one of the interactive components."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Please speak up also if you see something missing. ",
        "annotations": {
            "encourage participation": "The speaker invites others to contribute to the discussion, especially if they see something missing.",
            "process management": "The speaker is managing the discussion flow by encouraging participation and ensuring all voices are heard."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): Yes, please. ",
        "annotations": {
            "supportive response": "The utterance 'Yes, please' expresses agreement and encourages further discussion, fitting the definition of a supportive response.",
            "encourage participation": "The use of 'please' in the utterance invites further conversation or sharing of thoughts, encouraging participation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Sorry, I'm reading as you write because I'm going to have to run to teach right after we close. So if I don't eat now, I won't eat in like three hours. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): Of course. ",
        "annotations": {
            "acknowledge contribution": "Erin is verbally recognizing Rosa's input without adding new content.",
            "supportive response": "Erin is expressing agreement or validation with Rosa's situation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And and you're you're writing there needs for high throughput screening, but maybe we can also add a bullet point of there are some lower throughput screening methods that might be good to test specific hypothesis, but we need to get there. We need to know which specific hypothesis we want to be testing. What do you guys think? ",
        "annotations": {
            "propose new idea": "The speaker suggests considering lower throughput screening methods for testing specific hypotheses.",
            "develop idea": "The speaker builds upon the idea of high-throughput screening by suggesting an additional approach.",
            "ask question": "The speaker requests opinions from the group with 'What do you guys think?'."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Feel free to correct it or add something else. I'm just trying to get other people help Erin. ",
        "annotations": {
            "encourage participation": "The speaker invites others to contribute to the discussion, offering help to Erin."
        }
    },
    {
        "utterance": "Melanie Gareau (UC Davis): Erin, it's using with ING not AR, I just noticed. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it is a minor correction not directly related to the main discussion topics of proposing ideas, asking questions, or directly interacting on the main subject matter."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): Okay, thanks. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell, Iowa State University (he/his): Does anybody here been gotten successfully funded by the bylog? ",
        "annotations": {
            "ask question": "Tom is requesting information from the group about their experience with getting funded by a possibly misunderstood or misspoken entity."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): I didn't last year. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell, Iowa State University (he/his): I we didn't either. ",
        "annotations": {
            "code name": "None",
            "explanation": "The utterance is a brief acknowledgment and does not explicitly fit into any of the detailed codes provided."
        }
    },
    {
        "utterance": "Tom Mansell, Iowa State University (he/his): Uh ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I know I know someone at ASU that got funded last year by the way. Abishek, I don't know if you met him last year. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dave Durgan- Baylor College of Medicine: Yeah, I was a partner on that. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges their role as a partner in a project, recognizing their contribution."
        }
    },
    {
        "utterance": "Tom Mansell, Iowa State University (he/his): Okay, there you go. I'm just thinking that for their purposes like so you think that okay, so if you go to NIH with this idea, right? If you're talking about high throughput high throughput screens immediately a reviewer says this is a fishing expedition. This is hypothesis generating go somewhere else, right? Do you think that these guys are keen to fund that kind of thing or like hypothesis generation, which would be too risky for NIH or do you think that they're more translationally focused on that? Okay, we have a hypothesis now let's let's translate it. Like which on which side of like NIH do you think that that they sit? ",
        "annotations": {
            "ask question": "The speaker is asking a question about the NIH's focus and willingness to fund certain types of research.",
            "clarify goal": "The speaker is discussing the goals and potential focus of research funding but not defining objectives for the group."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: There's a on the high risk high yield I thought. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell, Iowa State University (he/his): High risk high yield, right? So it's ",
        "annotations": {
            "Supportive Response": "Tom Mansell is expressing agreement or validation of a previous point made about high risk, high yield research, indicating a supportive tone."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah. So I um I confess I was invited to be part of the review panel last year, but I wasn't. So I wish I had been there so I could give you an answer of like what the panel was actually looking for. The we didn't get a lot of feedback either, so that was. The and I I can you can provide that on your surveys as a comment that it would be helpful to get some feedback on your proposals so they know what you're they're looking for, right? And I can provide that too since I heard it from you, but my guess is that the the idea of this is to get funding that NIH wouldn't fund funded, you know, or get you started. For the record, I have NIH funding, but not to do autism and microbiome. What I showed today is work that has been done with small foundations and small and slightly larger pots of money, but not with NIH money because NIH has not been convinced that the gut microbiome is involved in this. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev, WCM, Cornell University: Yeah, it's it's really crazy. I I had like two grants not discussed there is a cell paper. It's just ridiculous. Yeah. ",
        "annotations": {
            "critical response": "The speaker expresses frustration and disappointment with the current state of grant discussions or publications, implying a negative evaluation."
        }
    },
    {
        "utterance": "Iliyan Iliev, WCM, Cornell University: Anyway, so ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So so those are the mechanisms here, yeah. ",
        "annotations": {
            "summarize conversation": "The speaker is concluding that the previously discussed points are the mechanisms."
        }
    },
    {
        "utterance": "Pamela Chang, Cornell: Are there other sorry, this is getting a little off topic, but are there other foundations that would be interested in funding gut microbiome research because I had a similar experience with NIH. I don't know if anyone else found alternatives. I mean aside fromlog. ",
        "annotations": {
            "ask question": "Pamela Chang asks if there are other foundations interested in funding gut microbiome research, sharing her experience with NIH and seeking alternatives."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I I would say um my with my knowledge and my experience because there might be others, they're more like disease specific. So I've gotten I've gotten funding from Autism Research Institute and Autism speaks. They're more to the disorder that you're targeting. And and and I also want to mention because I'm a reviewer at NIH that one of the challenges at NIH is that right now microbiome is everywhere. So what they do is you send a proposal that has some microbiome component, they send it to a panel that is investigating, I'm going to put aging as an example, okay? So aging and the microbiome. So they send it to an aging panel where no one there knows about the microbiome, but they call someone like Rosie to be the microbiome expert. And no matter how much Rosie likes that proposal, there's other reviewers that don't maybe don't appreciate the value of the microbiome. So unless Rosie is super outspoken and super defense that proposal and super is able to articulate the importance of the microbiome there, the proposal will not get funded. ",
        "annotations": {
            "signal expertise": "The speaker mentions their expertise as a reviewer at NIH.",
            "identify gap": "The speaker identifies a gap in knowledge or appreciation for microbiome research within NIH review panels.",
            "offer feedback": "The speaker offers insights and suggestions based on their experience with funding proposals for microbiome research."
        }
    },
    {
        "utterance": "Iliyan Iliev, WCM, Cornell University: And especially if you end up in a study section when you know, they are already established for a long time, if it goes to brain study section, you come withologist, what are you talking about? We study circuits here, you're dead. So ",
        "annotations": {
            "code name": "critical response",
            "explanation": "The speaker is questioning and challenging the current study section system and its ability to fairly evaluate interdisciplinary research proposals."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: You're absolutely right and I did it as a full professor. I don't know that this assistant professor. Like I agree with you, you know? Yeah. Some institutes are more open. Some institutes will say you know, um as long as you're doing good work. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and validation for the previous speaker's concerns about funding.",
            "process management": "The speaker is discussing the process of funding and research management, sharing insights from her experience."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: and the money eventually comes in anyhow, right? Because that money is coming in for me to pay postdocs and for me to pay supplies and it has to come into the institution. ",
        "annotations": {
            "process management": "The speaker is discussing how funding for research comes into the institution for expenses such as paying postdocs and supplies."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, I mean the institution I'm right now, they're very supportive to that one time it will fly, but I was in another institution and I brought a grant that just gave like 5% or something and they asked me to find other 45% to pay to the institution. So so yeah, so it depends on the institution as well, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Foundations are really good and if you guys can get something funded through Silog that might help you get preliminary data for NIH. ",
        "annotations": {
            "offer feedback": "The speaker provides a suggestion for securing funding, offering a potential strategy for obtaining preliminary data for NIH."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And meeting people here also might help you at NIH because some of these people might end up in panels, you know, and might recognize that you are doing good work. ",
        "annotations": {
            "offer feedback": "The speaker provides advice on how to improve chances with NIH, suggesting that networking could help in getting recognized by panel members.",
            "encourage participation": "The speaker encourages networking as a way to potentially improve one's standing with NIH.",
            "process management": "The speaker provides guidance on how to navigate the funding process, specifically regarding the importance of personal connections."
        }
    },
    {
        "utterance": "Erin Longbrake: Are you guys happy with our report slide just to ",
        "annotations": {
            "process management": "The speaker is managing the discussion flow by seeking feedback on a shared report slide."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Sorry Erin. ",
        "annotations": {
            "supportive response": "The speaker is expressing apology, which is a form of showing consideration for the other person's feelings, thus it's a supportive response."
        }
    },
    {
        "utterance": "Erin Longbrake: No, no, no. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: amazing. Thanks a lot for doing that. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges someone's effort and contribution.",
            "supportive response": "The speaker expresses a positive sentiment and validation."
        }
    },
    {
        "utterance": "Erin Longbrake: Can we potentially go back to that for two minutes to make sure this isn't just me making stuff up. ",
        "annotations": {
            "Ask Question": "The speaker is requesting to revisit a previous topic to ensure understanding, which is a clear request for information or clarification."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, and thank you. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes another group member's input or contribution."
        }
    },
    {
        "utterance": "Erin Longbrake: anything I missed. ",
        "annotations": {
            "ask question": "Erin Longbrake is seeking information about anything she might have missed in the discussion, indicating a request for clarification or additional information."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Do you have the, can you pull back the can the can then move iteratively or you want you want it there? ",
        "annotations": {
            "process management": "The speaker is trying to manage the discussion or the use of a tool/methodology, seeking clarification on how something can be moved or used iteratively."
        }
    },
    {
        "utterance": "Erin Longbrake: Where do you want it? You want it over there? ",
        "annotations": {
            "ask question": "The speaker is requesting clarification or direction, which is a direct question."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I don't know. I'm asking you if you wanted if if it was there on purpose. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification about someone's intentions or actions."
        }
    },
    {
        "utterance": "Erin Longbrake: It was supposed to be a bullet point under the one above, but it didn't format the way I thought it was going to. ",
        "annotations": {
            "process management": "The speaker is commenting on the formatting issue with their contribution to the report, indicating a concern with the process of creating and organizing the meeting's output."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Oh, okay, okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Is there anything additionally that I just big top picks that I neglected to put on here? ",
        "annotations": {
            "ask question": "Erin Longbrake is requesting information or clarification on what else should be included or mentioned.",
            "encourage participation": "Erin Longbrake is inviting others to contribute their thoughts or suggestions."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I think um, we mentioned Funsize at some point and I don't I don't see it anywhere. ",
        "annotations": {
            "Summarize conversation": "Rosa Krajmalnik-Brown is trying to recall and reference a previous part of the conversation.",
            "Process management": "She is managing the flow of conversation and documentation by pointing out a missing topic."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I don't know if we want to call it out or not. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, there you go. Thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: All right. If you guys are happy with that, we can go back to the funding discussion, which is probably more high yield anyway. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by suggesting a change in topic from the current discussion to the funding discussion."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Are you guys okay with that? Are you all okay with that? ",
        "annotations": {
            "process management": "Checking for agreement on the discussion summary or decisions made."
        }
    },
    {
        "utterance": "Faranak Fattahi: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Okay. I'm sorry, I didn't mean to divert the I was just trying to answer and help Tom. ",
        "annotations": {
            "process management": "Managing the meeting flow and apologizing for potentially diverting the conversation."
        }
    },
    {
        "utterance": "Erin Longbrake: No, it was a high yield discussion and one that's definitely valuable. I just wanted to before we got dumped out, make sure that I was appropriately group centered on what I was reporting back. ",
        "annotations": {
            "acknowledge contribution": "Erin Longbrake acknowledges the value of the discussion and the contributions made."
        }
    },
    {
        "utterance": "Erin Longbrake: Thank you. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: NIH is really difficult. I just um, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: They don't like funding anything that's risky and there's a bias towards hypothesis. I I I don't fully buy into this like has to be hypothesis generated research. There's so much that we don't know you have to do observations before you can generate a hypothesis. So who's going to fund the observations? ",
        "annotations": {
            "ask question": "Erin asks a question about who will fund observations.",
            "identify gap": "Erin points out the gap in funding for observational research necessary for generating hypotheses.",
            "critical response": "Erin critiques the current funding approach, emphasizing a bias against risky research and the importance of observations."
        }
    },
    {
        "utterance": "Iliyan Iliev: Start up package. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, I mean it just seems it seems ridiculous. ",
        "annotations": {
            "critical response": "Erin is expressing frustration or disbelief about the situation, implying a negative evaluation of the current state of affairs with funding."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging a prior statement or contribution from another group member."
        }
    },
    {
        "utterance": "Erin Longbrake: and and very inducing. So I don't know. There seems at least at my institution, there's a fair amount of um snobbery when it comes to being NIH funded versus not NIH funded. And I have a fair amount of pharma funding right now, which is good for me, but doesn't have the same cache for promotion and tenure or whatever. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dave Durgan: That's the thing. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's the thing that for promotion and tenure, if you have an R1, it speaks volumes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: It brings money, right? ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it is more of a rhetorical comment than a contribution that fits into one of the specified categories."
        }
    },
    {
        "utterance": "Erin Longbrake: Maybe it shouldn't. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: We're about we're about to be kicked out. I think they wanted to say something before we get kicked out. ",
        "annotations": {
            "process management": "The speaker is indicating a concern about the meeting time, suggesting they are about to be kicked out, which relates to managing the meeting flow."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: No. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: No, this has been great. ",
        "annotations": {
            "supportive response": "Tom Mansell is expressing appreciation for the discussion."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, that was a great discussion. ",
        "annotations": {
            "supportive response": "The speaker is expressing a positive evaluation of the discussion that has taken place."
        }
    },
    {
        "utterance": "Faranak Fattahi: Yeah, thank you all. Thank you Erin for putting the slides together. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes another group member's input, specifically thanking Erin for putting the slides together."
        }
    },
    {
        "utterance": "Tom Mansell: Yeah, thank you Erin. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and appreciation for Erin's contribution."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Thank you. I'm sorry I got kicked out in the middle. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: You were you were back fast. It was great. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and a positive sentiment towards Rosa Krajmalnik-Brown's quick return to the conversation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Um, on the NIH, keep on pursuing it and talk to program directors. That's my advice because I I actually have two R1s funded and it wouldn't have happened if I hadn't talked to program directors and pursuing it and keep keep on trying, make it better, talk to program directors. That's my advice. ",
        "annotations": {
            "offer feedback": "Provides specific suggestions for improvement based on personal experience.",
            "encourage participation": "Encourages others to continue pursuing funding opportunities."
        }
    },
    {
        "utterance": "Tom Mansell: All right, thanks everyone. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Faranak Fattahi: Thanks. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    }
]